糖尿病患者骨质量评估
糖尿病与骨质疏松性骨折风险升高相关,骨密度和FRAX可能低估糖尿病患者骨折风险;本文综述骨小梁评分、外周定量CT、微压痕、骨组织形态计量学和骨转换标志物等骨质量评估方法的发展与临床应用。
要点
- 骨密度和FRAX可能低估糖尿病患者的骨折风险。
- 骨小梁评分和外周定量CT有助于评估糖尿病患者的骨质量和骨折风险。
- 微压痕和骨组织形态计量学是有创评估方法,可补充现有骨分析技术。
核心结论
- 大量证据表明糖尿病与骨质疏松性骨折风险升高相关,低骨强度及骨外因素可能促成糖尿病患者的骨脆性增加。
- 骨密度和FRAX是评估骨强度的有用临床工具,但可能低估糖尿病患者的骨折风险。
- 骨小梁评分和外周定量CT等新技术有助于更好地评估糖尿病患者的骨质量和骨折风险。
研究设计与样本
- 本文为综述,总结骨质量评估方法的发展与临床应用。
主要发现
- 骨密度和FRAX可能低估糖尿病患者的骨折风险。
- 骨小梁评分和外周定量CT可更好地评估糖尿病患者的骨质量和骨折风险。
- 微压痕和骨组织形态计量学等有创评估是现有骨分析技术的重要补充。
- 糖尿病患者的骨转换标志物存在改变,可能与骨折相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Substantial evidence exists that diabetes mellitus is associated with an increased risk of osteoporotic fractures. Low bone strength as well as bone extrinsic factors are probably contributing to the increased bone fragility in diabetes. Bone density and quality are important determinants of bone strength. Although bone mineral density (BMD) and the fracture risk assessment tool (FRAX) are very useful clinical tools in assessing bone strength, they may underestimate the fracture risk in diabetes mellitus. Through advances in new technologies such as trabecular bone score (TBS) and peripheral quantitative computed tomography (pQCT), we can better assess the bone quality and fracture risk of patients with diabetes mellitus. Invasive assessments such as microindentation and histomorphometry have been great complement to the existing bone analysis techniques. Bone turnover markers have been found to be altered in diabetes mellitus patients and may be associated with fractures. This review will give a brief summary of the current development and clinical uses of these assessments.
引用
- Jiang N, Xia W. Assessment of bone quality in patients with diabetes mellitus. Osteoporos Int. 2018. PMID: 29736760. doi:10.1007/s00198-018-4532-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。